engleski

Antitumor effect of bee venom and melittin in vitro

Bee venom therapy has been used as a traditional medicine to treat a variety of illness, such as arthritis, rheumatism, back pain, tumours, and skin diseases. To test antitumor potential of domestic Apis mellifera bee venom (BV) we used selected cell lines, tumour colon adenocarcinoma (CaCo-2), cervix adenocarcinoma (HeLa), Burkitt lymphoma (RAJI), chronic myeloid leukaemia in blasted crisis (K562) of human origin and Madine-Darby canine kidney (MDCK) cells. Final concentration range of BV was 0.001 to 1 mg/ml. As a standard compound was used melittin in a concentration range of 0.001 to 0.1 mg/ml. The cytotoxic effect of BV and melittin were evaluated after 72 hours of incubation by the MTT assay. Apoptosis was performed on HeLa cell line in the presence of the BV (IC50 =0.07mg/ml) for various times. Obtained results showed that leukaemia cells were more sensitive to BV and melittin. The 50% survival of treated tumor adherent cell (IC50) was achieved by application of 0.1 mg/ml of BV and melittin. As expected, the most resistant to BV and melittin was normal MDCK cells. BV cause apoptosis in HeLa cells in concentration of 0.07mg/ml after 6 and 24 hourse. BV as a natural remedy, through the activity of lytic peptides melittin, can be useful as a new targeted therapy in anticancer treatment.

Bee venom; Melittin; Antitumor potential; Apoptosis

nije evidentirano